Olokizumab showed promise for RA patients nonresponsive to antitumor necrosis factor therapies

Olokizumab, a humanized monoclonal antibody specific for the interleukin-6 cytokine, showed promise for patients with rheumatoid arthritis who had an inadequate response to antitumor necrosis factor...